Lipids Unresolved

Release Date: January 20, 2012
Expiration Date: January 20, 2013



	How to Obtain AMA PRA Category 1 Credit™ Watch the webcast. Complete the posttest (each question must be answered correctly). Login to your account. Complete the credit and evaluation form. Print your personalized CME certificate. Technical Requirements

Estimated Time of Completion: 2 hours 30 minutes

Description

The Lipids Unresolved webcast reviews the latest research, knowledge, and skills needed to identify patients who remain at risk for cardiovascular (CV) events, and evaluate emerging strategies that decrease residual CV risk. Expert faculty presenters include their perspectives and interpretations of current clinical trial data regarding the future management of patients with cardiovascular disease.

Learning Objectives

Discuss the effect of HDL-C level on risk for CHD.
Explain controversies regarding statins, inflammation, and the JUPITER study.
Discuss the effect of cholesteryl ester transfer protein inhibitors and modulators on HDL-C remodeling.
Assess the potential benefits of niacin beyond its lipid effects.
Indicate the frequency and secondary causes of statin intolerance and treatment options for statin-intolerant patients.
Review the scientific research publications relating to adherence to lipid-lowering therapies and the potential impact on current treatment decisions.

Target Audience

This activity is directed to physicians and health care providers involved in prevention of cardiovascular disease.

Accreditation

The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this enduring activity for a maximum of 2.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

Activity Directors

Stephen J. Nicholls, MD, PhD
Medical Director, Intravascular Ultrasound and
Angiography Core Laboratories
Clinical Director, Center for Cardiovascular Diagnostics and Prevention
Associate Director, Coordinating Center for Clinical Research
Assistant Professor of Molecular Medicine
Cleveland Clinic Lerner College of Medicine at
Case Western Reserve University
Cleveland Clinic
Cleveland, OH

Steven Nissen, MD
Professor of Medicine
Chairman, Tomisch Department of Cardiovascular Medicine
Heart and Vascular Institute
Cleveland Clinic
Cleveland, OH

Katherine J. Hoercher, RN
Senior Director of Special Programs
Kaufman Center for Heart Failure
Heart and Vascular Institute
Cleveland Clinic
Cleveland, OH

Faculty

Christie M. Ballantyne, MD
Chief, Cardiovascular Research Section
Division of Atherosclerosis and Vascular Medicine
Professor of Medicine
Baylor College of Medicine
Houston, TX

Philip J. Barter, MD, MBBS, PhD
Director, The Heart Research Institute
Sydney, Australia

Bryan Brewer, MD
Director, Washington Cardiovascular Associates
Senior Research Consultant, Medstar Research Institute
Washington, DC

Michael Davidson, MD
Clinical Professor of Medicine
Director, Preventive Cardiology
University of Chicago
Chicago, IL

John J.P. Kastelein, MD, PhD
Professor of Medicine
Strategic Chair of Genetics of Cardiovascular Disease
Chairman of the Department of Vascular Medicine
Academic Medical Center of the University of Amsterdam
Amsterdam, The Netherlands

A. Michael Lincoff, MD
Vice Chairman
Tomsich Department of Cardiovascular Medicine
Heart and Vascular Institute
Cleveland Clinic
Cleveland, OH

Daniel J. Rader, MD
Penn CVI Scientific Director for Translational/Clinical Research Professor
University of Pennsylvania
Philadelphia, PA

Disclosure

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty members have indicated that they may have a relationship which, in the context of their presentation, could be perceived as a potential conflict of interest:

Christie M. Ballantyne, MD
	Abbott; GlaxoSmithKline; Merck	Consulting, Grant/Research Support, Honorarium, and Speakers Bureau

	ADA; AHA; diaDexus; NIH	Grant/Research Support

	Adnexus; Amylin; Esperion; Genentech; Idera Pharma; Omthera; Resverlogix	Consulting

	AstraZeneca; Sanofi-Synthelabo; Takeda	Consulting, Grant/Research Support, and Honorarium

	Bristol-Myers Squibb; Kowa; Novartis; Roche	Consulting and Grant/Research Support

Philip Barter, MD, MBBS, PhD
	Merck; Roche	Membership on Advisory Committee, Teaching and Speaking

Bryan Brewer, MD
	Eli Lilly; Merck	Consulting

	HDL Therapeutics	Ownership Interest

	Roche	Consulting, Teaching and Speaking

Michael H. Davidson, MD
	Amgen; Merck; Roche; sanofi-aventis	Membership on Advisory Committee

	Omthera Pharmaceuticals	Ownership interest

A. Michael Lincoff, MD
	Roche	Grant/Research Support, Independent Contractor

Stephen Nicholls, MD, PhD
	Anthera; Eli Lilly; Novartis; Resverlogix	Independent Contractor

	AstraZeneca; Roche	Consulting and Independent Contractor

	Merck; Omthera; sanofi-aventis; Takeda	Consulting

Daniel J. Rader, MD
	Aegerion Pharmaceuticals; VascularStrategies	Ownership Interest

	Alnylam; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Eli Lilly; GlaxoSmithKline; Johnson and Johnson; Merck; Novartis; Omthera; Pfizer; Regeneron; sanofi-aventis	Consulting

The following faculty have indicated they have no relationship which, in the context of their presentation, could be perceived as a potential conflict of interest:

Katherine J. Hoercher, RN
John J.P. Kastelein, MD, PhD
Steven Nissen, MD

Acknowledgements

The Cleveland Clinic Foundation Center for Continuing Education acknowledges
educational grants for partial support of this activity from:

Genentech
LipoScience.
Resverlogix Corp

This CME activity was produced by the Cleveland Clinic Foundation Center for Continuing Education and Heart and Vascular Institute.

CME Disclaimer